CDC Merges Flu and COVID Divisions
The Centers for Disease Control and Prevention is merging its Influenza Division with the Coronavirus and Other Respiratory Diseases Division to create the Influenza and Respiratory Viruses Division.
New COVID Vaccines Approved by FDA
Updated COVID-19 vaccines from Moderna, Novavax-Sanofi and Pfizer-BioNTech have been approved by the U.S. Food and Drug Administration.
COVID-19 and Influenza Coadministered Vaccines May Loiwer Risk of MACE in Older Adults
According to a recent study, coadministration of the COVID-19 vaccine with the annual influenza vaccine may reduce COVID-19-related major adverse cardiovascular events (MACE) among older adults, especially those with comorbidities. In the study, researchers conducted a target trial emulation using electronic health record data of more than one million veterans (mean age, 70 years; 92 […]
COVID-19 Vaccines Lower Risk of Heart Attack and Cardiac Death
ccording to three different studies, COVID-19 vaccines were associated with a lower risk of major adverse cardiovascular events (MACE), in addition to other outcomes, particularly among older adults.
Study Finds Moderna and Pfizer/BioNTech COVID-19 Vaccines 70 to 76 Percent Effective Against Severe Illness in Kids
A recent study in Taiwan that examined the vaccine effectiveness (VE) against moderate to severe COVID-19 infection in children aged 6 to 11 years found the Pfizer/BioNTech BNT162b2 VE was 69.9 percent and the Moderna mRNA-1273 VE was 75.5 percent during Omicron BA.2/BA.5 predominance in 2022.
WHO and CDC: Preparing for the Next Pandemic
Changes to guidance from the WHO and CDC should strengthen preparedness and response to future potential pandemic diseases.
Researchers Discover Why a Rare Blood Clot Occurs After COVID-19 Vaccination
Researchers have discovered why the unusual side effect of a blood clot that impacted some recipients of the Oxford/AstraZeneca and Johnson & Johnson COVID-19 vaccines occurred.
Vaccine Against SARS Virus Family Enters Human Clinical Trials
A vaccine candidate called GBP511 that builds upon a self-assembling nanoparticle technology has begun human clinical testing in Australia.
SARS-CoV-2 and COVID-19: Plasma Supply and IG Replacement Therapy to Protect Immunodeficient Patients
Can anti-SARS-CoV-2 antibodies in the plasma supply protect against COVID infection in
immunodeficient patients? Research suggests otherwise.
Study Shows No Causal Relationship Between COVID-19 Vaccination and Myositis
According to a study that analyzed the Veteran’s Health Administration records found there is no evidence to suggest COVID-19 vaccination increases the risk of developing idiopathic inflammatory myositis.